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Supplementary Figure 1. Classification of non-silent mutations found in 2,105 tumors. Most 














Supplementary Figure 2. Mutations in genes involved in DNA replication or repair in 
hypermutated MSS tumors without mutations in the POLE and POLD1 genes. Mutations in 
DNA replication or DNA mismatch repair are shown in different colors. 
WNT/beta-catenin signaling pathway
Supplementary Figure 3. Contributions of genes with somatic mutations in selected pathways in non-hypermutated 

































































































Supplementary Figure 4. Distribution of somatic mutations in APC, TP53, and KRAS mutated tumors. Green, 
black, and brown circles denote missense mutations, truncations, and in-frame indels, respectively. Colored boxes 






Supplementary Figure 5. Codons affected by recurrent mutations in KRAS, NRAS, and BRAF. 
Hypermutated (HM) and non-hypermutated (NHM) tumors exhibit differences in mutated codons in 
these genes. 
Supplementary Figure 6. Non-silent mutations in 64 MSS-hypermutated tumors without 
mutations in the POLE and POLD1 genes. The top 50 mutated genes are shown. 
Supplementary Figure 7. Mutations types across hypermutated tumors, with MSI, or MSS 
tumors with and without nonsilent mutations in POLE/POLD1. UTR = untranslated regions 









Supplementary Figure 8. Separation of False Positive (FP) and True Positive (TP) somatic 
SNV calls. Data was plotted using log10 (read-depth in tumor) and log10 (alt read depth) for 
somatic SNVs from all 7 dilution samples.  
 
Supplementary Figure 9. Histogram of point mutations (SNVs) called in 2,105 colorectal tumors in 
the log-scale. The threshold to define a hypermutated tumor was set to 23.
Supplementary Figure 10. Defining the microsatellite status of tumors. The fraction of unstable 
microsatellite loci identified by the targeted panel (left) and cumulative distribution of that fraction 
(right). We decided on 12% unstable sites threshold to define MSI status, indicated by the dashed 





1. Design for the targeted sequencing panel 
 
To ensure the most comprehensive selection of putative relevant genes and other 
somatic mutations related to colorectal cancer (CRC) we used multiple sources and 
approaches to select the targeted sequencing panel. We included 700 whole exome 
sequencing paired normal-tumor (formalin-fixed paraffin embedded, FFPE) samples 
from Health Professional Follow up Study (HPFS) and the Nurses’ Health Study (NHS) 
and 525 whole exome sequencing paired normal-tumor (fresh frozen) samples from The 
Cancer Genome Atlas (TCGA) colon and rectal adenocarcinoma data 1–3. These two 
datasets were separately called and analyzed for somatic mutations.  Analyses were 
conducted stratified by hypermutated cases (defined as >=17 SNVs/Mb) vs non-
hypermutated samples. A primary inclusion criterion for selecting a gene was that the 
gene was significantly mutated (P<0.01 based on MutSigCV, details below) in non-
hypermutated cases in either the TCGA samples or the HPFS/NHS samples. 
Furthermore, we conducted pathway analysis based on the results from MutSigCV to 
identify CRC-related pathways and additional genes within relevant pathways.  We 
conducted nonrandom clustering analysis to identify additional genes with the gain of 
function mutations not identified otherwise. We evaluated the list of significantly mutated 
genes for the hypermutated samples based on HPFS/NHS and TCGA; however, as the 
list was very large and likely included a large number of false positive findings we only 
included a gene if additional evidence was available, such as relative low p-value in non-
hypermutated samples, support from the literature review or being located in highlighted 
pathways. In addition to these individual level data analyses, we conducted a literature 
search 4–13 and evaluated genes listed in COSMIC (http://cancer.sanger.ac.uk/cosmic) to 
identify additional genes. These approaches led to the selection of 205 genes. As MSI 
testing is possible with the next generation sequencing we included 236 
MSI/homopolymer markers. As a quality control measure, we included a gender marker.  
      
Prioritizing genes for inclusion in the targeted panel using MutSigCV 
 
We ran MutSigCV on the Mutation Annotation Format (MAF) files separately for 
HPFS/NHS and TCGA samples (both stratified by hypermutated vs non-hypermutated) 
using the MutSigCV package as described in 14. We used the covariates file provided by 
the Broad that accounts for the effect of DNA replication time, chromatin state 
(open/closed), and general level of transcription activity on the background mutation rate 
for each gene. To generate an accurate coverage file we used the exome kits, VCRome 
2.1 and Roche v2, used on the samples run on Solid (subset of TCGA samples) and 
Illumina respectively, taking the union of the exons included in each kit to define the 
gene, and the reading frame for each exon provided by the UCSC Genome Browser for 
the corresponding RefSeq transcript. We used the HUGO gene names and the RefSeq 
transcripts provided in the MAF. The genes to add to the panel were selected from the 




The HPFS/NHS and TCGA data was used to include genes connected to the main 
pathways involved in CRC which did not make the above-prioritized list of genes. A total 
of 19 additional genes were added from the datasets of non-hypermutated and 




Using non-random clustering to identify genes with gain of function mutations to add to 
targeted panel 
 
For the TCGA samples, we applied the nonrandom clustering method as described in 15 
using the longest RefSeq isoform stratified by hypermutated vs non-hypermutated 
samples. This resulted in a list of significant clusters of point mutations. If a gene 
contained a cluster with a p-value < 0.01, then this gene was included in the panel. 
Genes with significant clusters corresponding to single amino acids were given particular 
consideration for the panel. 
 
We also did nonrandom clustering restricted to indels to identify clusters of indels for 
consideration for the panel. Since many of the clusters corresponded to indels at 
homopolymers in the hypermutated set of samples, likely resulting from MSI, we 
considered this set separately and included genes containing indels at homopolymer 
that occurred in at least 5 samples. 
 
 
2. Somatic single nucleotide variants (SNVs) calling and filtering 
SNV calling 
Samples passing QC were selected for somatic mutation calling. We called somatic 
SNVs for each sample using both Strelka (version 1.0.15) and MuTect (version 1.1.7).  
 
We modified the default configuration of Strelka by removing the read-depth filter 
isSkipDepthFilters=1, according to the recommendation for analyzing exome/targeted 
sequencing data using Strelka 
(https://sites.google.com/site/strelkasomaticvariantcaller/home/faq).  
 
Both Strelka and Mutect require the reference genome sequence. In addition, Mutect 
also uses input of mutation annotation from COSMIC and dbSNP. We obtained these 
files from the following locations.  
 
● hg19 reference from UCSC Genome Browser website 
http://hgdownload.cse.ucsc.edu/goldenPath/hg19/bigZips/.  
● Cosmic somatic mutations 
We downloaded Cosmic somatic mutation vcf files for coding and non-coding 
variants (CosmicCodingMuts.vcf.gz and CosmicNonCodingVariants.vcf.gz) from 
Cosmic website (sftp-cancer.sanger.ac.uk/cosmic/grch37/cosmic/v76/VCF). 
Then sort these files according to the reference genome and merge them to one 
vcf file.  
● dbSNP annotations 
The dbSNP annotations (version 138) were downloaded from GATK bundle 
(ftp://gsapubftp-anonymous@ftp.broadinstitute.org/bundle/), and sorted 
according to the reference genome.  
 
We annotated the somatic mutation calls by ANNOVAR to obtain the functional 
consequence of somatic mutations, e.g., intergenic, intronic, or exonic, and if exonic, 
whether it is synonymous, missense, start gain/loss etc. In addition, ANNOVAR also 
provides annotation of alternative allele frequency in Exome Aggregation Consortium 
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(ExAC) version 0.3 while excluding TCGA studies (ExAC_nontcga_ALL). Such ExAC 




We retained a somatic SNV if it has a PASS status from both Strelka and MuTect or 
PASS from Strelka, and fail from MuTect only because of “clustered_read_position”. We 
rescued mutations that failed the “clustered_read_position” filter because the 
sequencing reads are clustered due to the design of our amplicon sequencing strategy. 
Customized filters on clustered reads were applied in the following steps: 
● Poor mapping quality, defined as more than 2% of covering reads have a 
mapping quality of 0 
● Strand bias, defined as a MuTect LOD score ratio of the forward and reverse 
strand to be >1000 or < 1e-3 
● MAF in ExAC to be > 1e-4  
● Read-depth in tumor or normal < 25 reads or < 5 reads supporting the alternative 
allele 
● Clustered read position: candidate SNV occurred in the first or second base of 
either end of reads supporting the mutation   
 
In addition to original sequencing run with default (100%) reagent concentration, we 
conducted three additional sequencing runs with 100%, 75%, and 50% dilution of 
reagent for 7 samples. We found the dilution of reagent does not have a significant 
impact on the number of somatic mutation calls and decided to use 50% diluted 
reagents in the following studies. Ignoring the factor of dilution, we essentially obtained 4 
replicates for 7 samples. 
 
We first use these replicates to evaluate the set of initial filtering criterion. As shown in 
Supplementary Table 2, most SNVs that are removed by our filters are called in only one 
of the four replicates, except the ExAC filter. It is expected that the mutations filtered by 
ExAC filter appear in multiple replicates because they are likely germline mutations.  
 
Further filtering based on read-depth and variant allele frequency 
We consider the mutations that appear once in the four replicates as False Positives 
(FPs), and the mutations that appear in all four replicates as True Positives (TPs). We 
seek to classify FPs and TPs. To remove redundancy of TPs (since one mutation is 
called in four replicates), we chose the one in 50% dilution to represent the four 
replicates of each TP. Our conclusion of FP/TP classification is robust to this choice. 
After the aforementioned initial round of filtering of SNVs, there are 147 SNVs appearing 
in one replicate, and 204 appear in four replicates.  
 
We manually examined the distributions of different characteristics of the remaining 
SNVs, such as read depth in tumor or normal samples, mutation call confidence score 
reported by MuTect or Strelka, and the number of alternative reads (i.e., the reads 
harboring alternative allele). It turns out that the FPs and TPs can be well separated in 
the two-dimensional space of log10(read depth in tumor) and log10(number of 
alternative reads) (Supplementary Figure 8). We applied linear discriminant analysis 
(LDA) (R function MASS/lda) to derive the classification rule: somatic SNV call is TP if 




log10(alt read depth) > -0.319 + 0.76*log10(tumor read-depth). 
 
Our samples can be divided into two groups based on read-depth in the paired normals. 
In the first batch, read-depth in paired normals is comparable to read-depth in tumors 
(median 522 and IQR [254, 851]), while the second batch, the read-depth in paired 
normal is significantly reduced (median 60 and IQR [35, 100]). To study the somatic 
mutation calling and filtering, we down-sampled the read-depth in paired normals of 
dilution samples to 1/10 of the original depth.  
 
Next, we applied the same steps of somatic mutation calling and initial filtering and then 
applied LDA to classify TP and FP somatic mutations. The resulting classification rule is 
 
 log10(alt read depth) > -0.225 + 0.73*log10(tumor read-depth). 
 
We applied one of these two LDA filtering depending on the read-depth in paired-normal 
samples.  
 
Amplicon artifact filtering 
Sanger sequencing of a subset of candidate mutations revealed another source of false-
positives: amplicon-specific mismatches. These false positives may occur during clonal 
amplification on the flow cell or during addition of fluorescently tagged nucleotides, which 
results in miscalled bases on either ends of the reads, but it is not limited to it. We 
identified strong amplicon artifacts present in any position of the reads, likely introduced 
during PCR-based library preparation. Hence, trimming candidates located in the first n 
bases of either end of the reads is considered both wasteful and insufficient. Instead, we 
decided to compare the number of reads supporting the alternative allele and number of 
reads supporting the reference allele between overlapping amplicon clusters -i.e., reads 
derived from the same primer pair covering a candidate mutation. This was determined 
by every read pair’s alignment start position. 
  
In other words, for each mutation, we generate a contingency C x 2 table, where C is the 
number of clusters and the two columns of this table correspond to the number of 
reference and alternative reads. Resulting contingency tables were evaluated by two 
methods and a candidate gets removed if both methods vote to reject: 
 
χ2 test of a contingency table if the total number of amplicon clusters is >1 and p-value is 
smaller than 5e-5 vote to reject.  
 
Cumulative sum, which is an ad-hoc statistic resembling Kolmogorov–Smirnov test 
statistic to compare two distributions. Here we compare the read count distributions 
between reference and alternative alleles. We apply the following steps to a contingency 
table to calculate this statistic: 
1. Order rows in a contingency table by the number of alternative read counts from 
high to low. 
2. Calculate cumulative sum of alternative and reference read counts. 
3. Divide each row by the total number of alternative and reference reads 
respectively (i.e., divide by the last row of the cumulative sum). 
4. Subtract reference read fraction from alternative read fraction for each cluster. 
5. Calculate a statistic d as the maximum of the alternative read fraction subtracted 
by the reference read fraction. 
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We removed a mutation if d > 0.35 and the number of clusters was >1. 
 
All “remove candidates” with more than two clusters were then tested again, but the 
cluster with the lowest VAF was removed to avoid over filtering due to misaligned reads.  
	
 
3. Short somatic InDel calling and filtering 
 
InDel calling 
To call somatic InDels, we used a majority-win approach, which requires two out of three 
callers, VarScan2 (2.4.3), VarDict (Feb 2017) and Strelka (1.0.15) to agree on an initial 
set of candidate InDels. 
VarScan2 input was generated from SAMtools (1.8) mpileup. It was configured to keep 
anomalous read pairs and per-Base Alignment Quality (BAQ) computation was disabled. 
Anomalous read pairs have parts of the forward and reverse read overlapping. BAQs are 
not expected by VarScan2 and, hence, not needed. Additionally, mapping qualities were 
adjusted by 50, as recommended by SAMtools and reads with a mapping quality of 3 or 
less were excluded. VarScan2 was configured to call somatic InDels with a minimum 
variant allele frequency of 0.05, a somatic p-value of < 0.05, strand-filter enabled (InDels 
with >90% strand bias are removed), minimum read coverage of 25 in tumor and normal 
and an expected tumor purity of 70%. Subsequently, VarScan2’s list of InDels was 
filtered for somatic status (SS) to be 2.  
 
VarDict was set up in paired variant calling mode with a minimum variant allele 
frequency of 0.05 and minimum mapping quality of 3. The minimum number of variant 
supporting reads was set to 4 and the highest variant allele frequency in normal was set 
to 1%. Subsequently, variant status (STATUS) was filtered for germline or any mutation 
type that was not a deletion or an insertion.  
 
Strelka was configured to skip the depth filter, as recommended for target sequencing 
data. Additionally, variants with allelic frequency of < 0.05 were removed from Strelka’s 
pass-filter output list.  
 
If two of the three callers called the same InDel (same locus and alternative allele), the 
variant was considered as candidate for further filtering or was removed otherwise. 
 
Candidate list was annotated by ANNOVAR to obtain further functional information, such 
as impact prediction and population frequencies. Annotated candidates that were called 
off-target were also removed prior filtering.  
 
InDel filtering 
Candidates were filtered for false-positives to obtain a final list of somatic InDels by 
applying the filter steps listed below. To keep coverage-based filtering consistent, per-
base coverage profiles for every position covered by the target amplicon panel, was 
generated using bam-readcount (https://github.com/genome/bam-readcount).  
Subsequently for each candidate, the somatic InDel VAF was obtained from # of alt-




Coverage and VAF filters 
 
A candidate is removed if the minimum total depth is less than 25x in normal and less 
than 200x in tumor. The number of reads supporting the alternative allele needs to be 10 
or higher. We also require a VAF ≥ 0.1 in the tumor.  For indels with 0.1 ≤ VAF < 0.2, we 
require a minimum total depth of 500x in tumor. 
 
Background filters  
 
We noticed background signals of alternative reads for indel calls in normal samples. 
More specifically, when examining the number of alternative reads versus the total 
number of reads in normal samples, the number of alternative reads increased linearly 
with increasing total read-depth. Such background, when appearing in a tumor, may lead 
to false positive indel calls. Therefore, we applied the following additional filters. 
 
Before background filtering, there are 15,021 indel calls from 4,920 unique indels. A 
unique indel is defined based on its location, reference allele, and alternative allele, and 
a unique indel may occur in multiple samples.  
 
For each unique indel, we obtained the alternative read count and total read-depth in all 
normal or tumor samples (regardless of being called in that sample or not). Then 
summarized such read counts using different percentiles as well the mean value of 
Variant Allele Frequency (VAF) as estimated by fitting a beta-binomial distribution on 
alternative read counts given total read counts.  
 
Using these statistics, we divided all 4,920 unique indels into three groups and every 
alternative allele at each position was tested separately.  
The first group includes 2,145 (~44%) unique indels that have alternative alleles in only 
one or two normals, with maximum VAF in normals <10%. This is the group of indels for 
which we did not apply additional filters.  
 
The second group includes 222 unique indels that were potential germline indels. We 
removed them in all samples. More specifically, an indel is a potential germline indel if 
Maximum VAF in normals >= 0.25, or 99.9 percentile >= 0.2, or mean VAF in normals 
>= 0.02. 
 
The remaining 2,553 unique indels had some background signals. We removed an indel 
call in a tumor sample if the alternative read count was not significantly larger than 
expected from the background distribution. For each indel, we obtained a background 
beta-binomial distribution fitted using the data from the normal samples. Then, for each 
tumor sample, we assessed the tail probability that the observed read count in this tumor 
sample may arise from the background beta-binomial distribution. If the tail probability is 
<10-5, we kept the indel, otherwise it was discarded.  
 







4. Quality control metrics 
 
To assess the quality of sequencing data, we examined various quality metrics using 
Picard (2.18.29). Median insert size -that is the number of base pairs between 
sequencing adapters of paired reads- for each tumor library was calculated using 
CollectInsertSizeMetrics. Hybrid-selection (HS) metrics for each tumor library were 
collected using CollectHsMetrics. HS metrics were used to calculate Read pass filter 
aligned ratio (PCT_PF_READS), AT drop out (AT_DROPOUT), GC drop out 
(GC_DROPOUT) and Percent target bases at 20X in tumor 
(PCT_TARGET_BASES_20X). Chimeric pairs ratio was determined from the tool 
CollectAlignmentSummaryMetrics (PCT_CHIMERAS). The OxoG Q-score was obtained 
from the PreAdapterSummaryMetrics of Picard’s CollectSequencingArtifactMetrics tool. 
The OxoG Q-score is the scaled probability for any given G:T transversion in a sample 
to be an artifact rather than a true mutation. Samples with OxoG Q score <35 are 
expected to have adverse impact on variant calling16. The lowest value among those 
samples passing QC filters was 44. The C>T variant combination proportion was 
calculated using the number of C>T mutations divided by the total number of SNV 
mutations after QC filtering. Because mutational burden, MSI status and mutations in 
POLE/POLD1 have substantial impact on the overall mutational profile, we show the 
quality control metrics stratified by these variables in Supplementary Table 3. The quality 
of the data is fairly consistent among groups defined by mutational burden, MSI status, 
and mutations in POLE/POLD. 
 
 
5. Description of participating studies 
 
Colorectal Cancer Study of Austria (CORSA) 
In the ongoing CORSA study, more than 16,000 Caucasian participants have been 
recruited within the province-wide screening project “Burgenland Prevention Trial of 
Colorectal Disease with Immunological Testing” (B-PREDICT) since 2003 17. All 
inhabitants of the Austrian province Burgenland aged between 40 and 80 years are 
annually invited to participate in fecal immunochemical testing and haemoccult positive 
screening participants are invited for colonoscopy. CORSA participants have been 
recruited in the four KRAGES hospitals in Burgenland, Austria, and additionally, at the 
Medical University of Vienna (Department of Surgery), the Viennese hospitals 
“Rudolfstiftung” and the “Sozialmedizinisches Zentrum Süd”, and at the Medical 
University of Graz (Department of Internal Medicine).  
 
Cancer Prevention Study II (CPS-II) 
The CPS-II Nutrition Survey cohort is a prospective study of cancer incidence and 
mortality in the United States, established in 1992 and described in detail elsewhere 18,19. 
At enrollment, participants completed a mailed self-administered questionnaire including 
information on demographic, medical, diet, and lifestyle factors. Follow-up 
questionnaires to update exposure information and to ascertain newly diagnosed 
cancers were sent biennially starting in 1997. Reported cancers were verified through 
medical records, state cancer registry linkage, or death certificates. The Emory 
University Institutional Review Board approves all aspects of the CPS II Nutrition Cohort. 
 
Darmkrebs: Chancen der Verhütung durch Screening (DACHS) 
This German study was initiated as a large population-based case-control study in 2003 
in the Rhine-Neckar-Odenwald region (southwest region of Germany) to assess the 
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potential of endoscopic screening for reduction of colorectal cancer (CRC) risk and to 
investigate etiologic determinants of disease, particularly lifestyle/environmental factors 
and genetic factors 20,21. Cases with a first diagnosis of invasive CRC (International 
Classification of Diseases 10 codes C18-C20) who were at least 30 years of age (no 
upper age limit), German speaking, a resident in the study region, and mentally and 
physically able to participate in a one-hour interview, were recruited by their treating 
physicians either in the hospital a few days after surgery, or by mail after discharge from 
the hospital. Cases were confirmed based on histologic reports and hospital discharge 
letters following diagnosis of CRC. All hospitals treating CRC patients in the study region 
participated. Based on estimates from population-based cancer registries, more than 
50% of all potentially eligible patients with incident CRC in the study region were 
included. During an in-person interview, data were collected on demographics, medical 
history, family history of CRC, and various life-style factors, as were blood and 
mouthwash samples. Formalin-fixed, paraffin-embedded, surgical specimens of CRC 
patients were collected from cooperating pathology institutes and transferred to the 
tissue bank of the National Center for Tumor Diseases in Heidelberg. 
 
Colon Cancer Registry (CCFR) 22.  
The CCFR is an NCI-supported consortium consisting of six centers dedicated to the 
establishment of a comprehensive collaborative infrastructure for interdisciplinary studies 
in the genetic epidemiology of colorectal cancer. The CCFR includes data from 
approximately 42,500 total subjects in 15,000 families (10,500 probands, and 26,770 
unaffected and affected relatives and 4,276 unrelated controls and 923 spouse controls). 
Cases and controls, age 20 to 74 years, were recruited at the six participating centers 
beginning in 1998. Between 1999 and 2002, female cases and controls 50-74 years 
enrolled into the Seattle CCFR (SCCFR) were subsequently enrolled in a 
complementary study of post-menopausal hormone use and CRC risk (PMH). The 
CCFR and PMH implemented a standardized questionnaire that was administered to all 
participants, and included established and suspected risk factors for colorectal cancer, 
including questions on medical history and medication use, reproductive history (for 
female participants), family history, physical activity, demographics, alcohol and women 
who also enrolled tobacco use, and dietary factors. This study selected tumor samples 
for these molecular subtypes study from two of the CCFR sites, Ontario and Seattle 























Study population      
     CORSA 171 67 0 0 NA 
     CPS-II 537 75 535 79 93.8 (85.4-102.7) 
     DACHS 200 69 198 31 60.6 (60.2-60.7) 
     OFCCR 674 58 514 89 194.1 (192.5-196) 
     SCCFR 523 58 433 117 170.9 (166.1-175.5) 
 
Sex 
     
     Female 1038 64 838 148 143.7 (133-155.3) 
     Male 1067 64 842 168 132.6 (123.2-146.5) 
 
Tumor cancer site 
     
     Right-sided 900 66 773 138 126.4 (113.2-139.8) 
     Left-sided 1184 62 900 177 148.2 (136.7-159.8) 
 
Tumor stage 
     
    Stage 1 or local 545 67 486 19 128.1 (116.4-138.9) 
Stage 2 or 3 or regional     1228 64 1041 201 145.5 (132.6-156.7) 
    Stage 4 distant 188 59 115 86 135.3 (89.8-190.1) 
 
Tumor hypermutation status 
     
    Non-hypermutated 1710 63 1340 290 148.4 (139.8-159.6) 
    Hypermutated 395 67 340 26 95.7 (83.1-112.5) 
 
Tumor MSI status 
     
   MSS 1795 63 1397 300 147 (138.7-157.3) 
   MSI 310 67 283 16 104.1 (90-117.2) 
* age at diagnosis reported in years. 




Supplementary Table 2. The number of somatic SNVs removed by each filter, grouped 
by the number of times a mutation is called. 
Filter name Number of times a mutation is called 
1 2 3 4 
Poor mapping  16 1 0 0 
Strand Bias  7 0 0 0 
Clustered Position  146 14 2 0 
ExAC MAF* 5 0 1 20 
Alternative reads 16 1 0 1 




Supplementary Table 3. Quality control metrics stratified by groups defined by 
hypermutation status, microsatellite status, and POLE/POLD1 mutation status. 
Quality control metrics Group 1* Group 2* Group 3* Group 4* All 
Number of samples 1,710 63 268 64 2,105 
Age of samples (mean)** 14.68 14.11 14.14 13.73 14.57 
Insert size (median) 123.1 120.8 122.7 120.7 122.9 
Read pass filter aligned ratio 0.996 0.989 0.996 0.993 0.996 
Chimeric pairs ratio 0.031 0.042 0.036 0.049 0.032 
AT drop out (%) 7.63 13.57 7.27 13.20 7.93 
GC drop out (%) 3.95 2.42 4.31 2.02 3.89 
Percent target bases at 20X in tumor 94.65 89.7 94.64 90.09 94.36 
C>T variant combination (%) 0.56 0.59 0.61 0.56 0.56 
OxoG Q-score (mean) 79.41 75.46 80.63 72.14 79.45 
*Group 1: NHM, Group 2: HM-MSS-POLE or POLD1 mutated, Group 3: HM-MSI, Group 
4: HM-MSS-non-POLE or POLD1 mutated; HM = hypermutated, NHM = non-
hypermutated, MSS = microsatellite stable, MSI = microsatellite instability 
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